دورية أكاديمية
Safety and efficacy of tixagevimab/cilgavimab for pre-exposure prophylaxis in kidney transplant recipients: a multicenter retrospective cohort study.
| العنوان: | Safety and efficacy of tixagevimab/cilgavimab for pre-exposure prophylaxis in kidney transplant recipients: a multicenter retrospective cohort study. |
|---|---|
| المؤلفون: | Simone S; Nephrology, Dialysis and Transplantation Unit, Department of Emergency and Organ Transplantation, University of Bari Aldo Moro, Bari, Italy., Pronzo V; Nephrology, Dialysis and Transplantation Unit, Department of Emergency and Organ Transplantation, University of Bari Aldo Moro, Bari, Italy., Pesce F; Nephrology, Dialysis and Transplantation Unit, Department of Emergency and Organ Transplantation, University of Bari Aldo Moro, Bari, Italy., Bavaro DF; Department of Biomedical Sciences and Human Oncology, Clinic of Infectious Diseases, University of Bari Aldo Moro, Bari, Italy., Infante B; Renal Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy., Mercuri S; Renal Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy., Schirinzi A; Clinic Pathology Unit, University Hospital of Bari, Bari, Italy., Panaro A; Nephrology, Dialysis and Transplantation Unit, Department of Emergency and Organ Transplantation, University of Bari Aldo Moro, Bari, Italy., Conte E; Nephrology, Dialysis and Transplantation Unit, Department of Emergency and Organ Transplantation, University of Bari Aldo Moro, Bari, Italy., Belati A; Department of Biomedical Sciences and Human Oncology, Clinic of Infectious Diseases, University of Bari Aldo Moro, Bari, Italy., Troise D; Renal Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy., Pontrelli P; Nephrology, Dialysis and Transplantation Unit, Department of Emergency and Organ Transplantation, University of Bari Aldo Moro, Bari, Italy., Conserva F; Nephrology, Dialysis and Transplantation Unit, Department of Emergency and Organ Transplantation, University of Bari Aldo Moro, Bari, Italy., Gallo P; Nephrology, Dialysis and Transplantation Unit, Department of Emergency and Organ Transplantation, University of Bari Aldo Moro, Bari, Italy., Panico M; Renal Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy., Spilotros M; Urology, Andrology and Kidney Transplantation Unit, Department of Emergency and Organ Transplantation, University of Bari 'Aldo Moro', 70124, Bari, Italy., Lucarelli G; Urology, Andrology and Kidney Transplantation Unit, Department of Emergency and Organ Transplantation, University of Bari 'Aldo Moro', 70124, Bari, Italy., Saracino A; Department of Biomedical Sciences and Human Oncology, Clinic of Infectious Diseases, University of Bari Aldo Moro, Bari, Italy., Stallone G; Renal Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy., Di Serio F; Clinic Pathology Unit, University Hospital of Bari, Bari, Italy., Ditonno P; Urology, Andrology and Kidney Transplantation Unit, Department of Emergency and Organ Transplantation, University of Bari 'Aldo Moro', 70124, Bari, Italy., Gesualdo L; Nephrology, Dialysis and Transplantation Unit, Department of Emergency and Organ Transplantation, University of Bari Aldo Moro, Bari, Italy. loreto.gesualdo@uniba.it. |
| المصدر: | Journal of nephrology [J Nephrol] 2024 May 23. Date of Electronic Publication: 2024 May 23. |
| Publication Model: | Ahead of Print |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer Country of Publication: Italy NLM ID: 9012268 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1724-6059 (Electronic) Linking ISSN: 11218428 NLM ISO Abbreviation: J Nephrol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2014- : Heidelberg : Springer Original Publication: Rome : Acta Medica, |
| مستخلص: | Background: Immunocompromised patients show an impaired vaccine response and remain at high risk of severe COVID-19, despite vaccination. Neutralizing monoclonal antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed for prophylaxis and treatment. The combination tixagevimab/cilgavimab (AZD7442) has been authorized for emergency use as pre-exposure prophylaxis for COVID-19, but data on safety and efficacy in kidney transplant recipients during the Omicron period are limited. Methods: We conducted a multicenter retrospective cohort study including 253 kidney transplant recipients, of whom 98 were treated with tixagevimab/cilgavimab 150 mg/150 mg and 155 who received only four doses of the BNT162b2 mRNA vaccine. Results: Only 13.3% of patients developed SARS-CoV-2 infection after the administration of tixagevimab/cilgavimab; in comparison, 34.2% of patients had been infected after the fourth dose of vaccine (p = 0.00013). Most infected patients in the AZD7442 group remained asymptomatic (92.3% vs 54.7%), 7.7% had mild symptoms and none had severe disease, need for hospitalization or died, while in the control group, 9.4% of patients had moderate or severe disease (p = 0.04). Using Kaplan-Meier curves we demonstrated that the controls presented early infection compared to the AZD7442 group (p = 0.000014). No changes in eGFR or proteinuria, assessed before and after the administration, were observed. Conclusions: In conclusion, our study showed that tixagevimab/cilgavimab 150/150 mg is effective and safe in preventing infection and severe disease when administered to patients with weak or no response to COVID-19 vaccine. (© 2024. The Author(s).) |
| References: | Haidar G, Mellors JW (2021) Improving the outcomes of immunocompromised patients with coronavirus disease 2019. Clin Infect Dis 73(6):e1397–e1401. (PMID: 10.1093/cid/ciab397339496448135839) Bergman P, COVAXID-Collaborator Group et al (2021) Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial. EBioMedicine 74:103705. (PMID: 10.1016/j.ebiom.2021.103705348614918629680) Ślizień Z et al (2022) Safety and tolerability of mRNA COVID-19 vaccines in kidney transplant recipients. Transplant Proc 54(4):878–883. (PMID: 10.1016/j.transproceed.2022.02.025359617348926897) Boyarsky BJ, Werbel WA, Avery RK et al (2021) Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA 325(21):2204–2206. (PMID: 10.1001/jama.2021.7489339501558100911) Rincon-Arevalo H et al (2021) Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. Sci Immunol 6(60):eanj1031. (PMID: 10.1126/sciimmunol.abj1031) Simone S et al (2023) Kinetics of humoral immune response and severity of infection after three doses of SARS-CoV-2 mRNA vaccine in a large cohort of kidney transplant recipients. J Nephrol 36(6):1663–1671. (PMID: 10.1007/s40620-023-01650-83745890910393874) Tixagevimab and cilgavimab (evusheld) for pre-exposure prophylaxis of COVID-19. JAMA. 2022;327(4):384–385. Abraham J (2022) Monoclonal antibodies with extended half-life to prevent COVID-19. N Engl J Med 386(23):2236–2238. (PMID: 10.1056/NEJMe2205563356751839202318) Levin MJ, Ustianowski A, De Wit S, Launay O, Avila M, Templeton A, Yuan Y, Seegobin S, Ellery A, Levinson DJ, Ambery P, Arends RH, Beavon R, Dey K, Garbes P, Kelly EJ, Koh GCKW, Near KA, Padilla KW, Psachoulia K, Sharbaugh A, Streicher K, Pangalos MN, Esser MT, PROVENT Study Group (2022) Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of COVID-19. N Engl J Med 386(23):2188–2200. (PMID: 10.1056/NEJMoa211662035443106) Benotmane I et al (2022) Pre-exposure prophylaxis with 300 mg evusheld elicits limited neutralizing activity against the Omicron variant. Kidney Int 102(2):442–444. (PMID: 10.1016/j.kint.2022.05.008356180949126611) https://www.epicentro.iss.it/coronavirus/sars-cov-2-monitoraggio-varianti-rapporti-periodici . Accessed 29 Apr 2022. Kim K, Cho K, Song J, Rahmati M, Koyanagi A, Lee SW, Yon DK, Il Shin J, Smith L (2023) The case fatality rate of COVID-19 during the delta and the omicron epidemic phase: a meta-analysis. J Med Virol 95(2):e28522. (PMID: 10.1002/jmv.2852236691933) Theodore DA, Branche AR, Zhang L, COVID-19 Prevention Network (CoVPN) et al (2023) Clinical and demographic factors associated with COVID-19, severe COVID-19, and SARS-CoV-2 infection in adults: a secondary cross-protocol analysis of 4 randomized clinical trials. JAMA Netw Open 6(7):e2323349. (PMID: 10.1001/jamanetworkopen.2023.233493744022710346130) Bahremand T et al (2023) COVID-19 hospitalisations in immunocompromised individuals in the Omicron era: a population-based observational study using surveillance data in British Columbia, Canada. Lancet Reg Health Am 20:100461. (PMID: 368908509987330) Chiang TP et al (2023) Incident COVID-19 and hospitalizations by variant era among vaccinated solid organ transplant recipients. JAMA Netw Open 6(8):e2329736. (PMID: 10.1001/jamanetworkopen.2023.297363759476310439474) Lauring AS, Influenza and Other Viruses in the Acutely Ill (IVY) Network et al (2022) Clinical severity of, and effectiveness of mRNA vaccines against, COVID-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ 376:e069761. (PMID: 10.1136/bmj-2021-06976135264324) Wong G et al (2022) COVID-19 infection with the omicron SARS-CoV-2 variant in a cohort of kidney and kidney pancreas transplant recipients: clinical features, risk factors, and outcomes. Transplantation 106(9):1860–1866. (PMID: 10.1097/TP.000000000000420335675438) Cristelli MP et al (2022) How did the omicron surge affect kidney transplant recipients compared with a cohort from the general population? Transplantation 106(8):e382–e383. (PMID: 10.1097/TP.0000000000004193355944759311286) Kneidinger N et al (2023) Outcome of lung transplant recipients infected with SARS-CoV-2/Omicron/B.1.1.529: a Nationwide German study. Infection 51:749–757. (PMID: 10.1007/s15010-022-01914-836083405) Kumar D et al (2022) Neutralization against Omicron variant in transplant recipients after three doses of mRNA vaccine. Am J Transplant 22(8):2089–2093. (PMID: 10.1111/ajt.17020352666069111417) Benning L et al (2022) Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients. Am J Transplant 22(7):1873–1883. (PMID: 10.1111/ajt.17054353842729111366) Fernandes G et al (2022) Monoclonal antibody therapy in kidney transplant recipients with delta and omicron variants of SARS-CoV-2: a single-center case series. Kidney Med 4(6):100470. (PMID: 10.1016/j.xkme.2022.100470354930299042411) Ducloux D, Courivaud C (2022) REGEN-Cov antibody combination to prevent COVID-19 infection in kidney transplant recipient without detectable antibody response to optimal vaccine scheme. Kidney Int 101(3):645–646. (PMID: 10.1016/j.kint.2021.12.015349956518724020) Al Jurdi A et al (2022) Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave. Am J Transplant 22(12):3130–3136. (PMID: 10.1111/ajt.1712835727916) Flahault A et al (2022) Breakthrough omicron COVID-19 infections in patients receiving the REGEN-Cov antibody combination. Kidney Int 101(4):824–825. (PMID: 10.1016/j.kint.2022.01.016351578948837470) Benotmane I et al (2022) Breakthrough COVID-19 cases despite prophylaxis with 150 mg of tixagevimab and 150 mg of cilgavimab in kidney transplant recipients. Am J Transplant. https://doi.org/10.1111/ajt.17121. (PMID: 10.1111/ajt.17121357139849800460) Kaminski H et al (2022) COVID-19 morbidity decreases with tixagevimab-cilgavimab preexposure prophylaxis in kidney transplant recipient nonresponders or low-vaccine responders. Kidney Int 102(4):936–938. (PMID: 10.1016/j.kint.2022.07.008358706419297679) Nguyen Y, Flahault A, Chavarot N et al (2022) Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld©) for COVID-19 among 1112 severely immunocompromised patients. Clin Microbiol Infect 28(12):1654.e1-1654.e4. https://doi.org/10.1016/j.cmi.2022.07.015. (PMID: 10.1016/j.cmi.2022.07.01535926762) Bertrand D et al (2022) Efficacy of anti-SARS-CoV-2 monoclonal antibody prophylaxis and vaccination on the Omicron variant of COVID-19 in kidney transplant recipients. Kidney Int 102(2):440–442. https://doi.org/10.1016/j.kint.2022.05.007 . (Epub 2022 May 23). (PMID: 10.1016/j.kint.2022.05.007356180979125992) Nagarajan R, Krishnamoorthy Y, Rajaa S, Hariharan VS (2022) COVID-19 severity and mortality among chronic liver disease patients: a systematic review and meta-analysis. Prev Chronic Dis 19:210228. (PMID: 10.5888/pcd19.210228) Moon AM, Webb GJ, Aloman C et al (2020) High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: preliminary results from an international registry. J Hepatol 73(3):705–708 (Epub 2020 May 21). (PMID: 10.1016/j.jhep.2020.05.013324467147241346) Liu Z, Hu D, Li J, Xia Q, Gong Y, Li Z, Wu Q, Yi M, Huang Y, Wu M, Guo L, Wu X (2021) Prognostic potential of liver enzymes in patients with COVID-19 at the Leishenshan Hospital in Wuhan. Front Cell Infect Microbiol 11:636999. (PMID: 10.3389/fcimb.2021.636999348690488635154) Roel E, Pistillo A, Recalde M et al (2021) Characteristics and outcomes of over 300,000 patients with COVID-19 and history of cancer in the United States and Spain. Cancer Epidemiol Biomarkers Prev 30(10):1884–1894 (Epub 2021 Jul 16). (PMID: 10.1158/1055-9965.EPI-21-0266342722628974356) Tian J, Yuan X, Xiao J et al (2020) Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. Lancet Oncol 21(7):893–903 (Epub 2020 May 29). (PMID: 10.1016/S1470-2045(20)30309-0324797907259911) Sengar M, Chinnaswamy G, Ranganathan P et al (2022) Outcomes of COVID-19 and risk factors in patients with cancer. Nat Cancer 3:547–551. (PMID: 10.1038/s43018-022-00363-435379984) Várnai C, Palles C, Arnold R et al (2022) Mortality among adults with cancer undergoing chemotherapy or immunotherapy and infected with COVID-19. JAMA Netw Open 5(2):e220130. (PMID: 10.1001/jamanetworkopen.2022.0130351885518861846) Bruel T, Hadjadj J, Maes P et al (2022) Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. Nat Med 28:1297–1302. https://doi.org/10.1038/s41591-022-01792-5. (PMID: 10.1038/s41591-022-01792-535322239) Benotmane I et al (2022) A rapid decline in the anti-receptor-binding domain of the SARS-CoV-2 spike protein IgG titer in kidney transplant recipients after tixagevimab-cilgavimab administration. Kidney Int 102(5):1188–1190. https://doi.org/10.1016/j.kint.2022.07.022 . (Epub 2022 Aug 13). (PMID: 10.1016/j.kint.2022.07.022359735959375643) Gilbert PB et al (2022) A covid-19 milestone attained—a correlate of protection for vaccines. N Engl J Med 387(24):2203–2206. (PMID: 10.1056/NEJMp221131436507702) Follmann D et al (2023) Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration. Nat Commun 14(1):3605. (PMID: 10.1038/s41467-023-39292-w3733060210276829) Akinosoglou K, Rigopoulos EA et al (2022) Tixagevimab/cilgavimab in SARS-CoV-2 prophylaxis and therapy: a comprehensive review of clinical experience. Viruses 15(1):118. (PMID: 10.3390/v15010118366801609866621) Keam SJ (2022) Tixagevimab + cilgavimab: first approval. Drugs 82(9):1001–1010. (PMID: 10.1007/s40265-022-01731-1357275639211051) Karaba AH, Kim JD, Chiang TP, et al. Omicron BA.1 and BA.2 Neutralizing activity following pre-exposure prophylaxis with tixagevimab plus cilgavimab in vaccinated solid organ transplant recipients. medRxiv [Preprint]. 2022:2022.05.24.22275467 (Update in: Clin Exp Rheumatol. 2023 Feb 23). VanBlargan LA et al (2022) An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat Med 28(3):490–495. https://doi.org/10.1038/s41591-021-01678-y . (Epub 2022 Jan 19). (PMID: 10.1038/s41591-021-01678-y350465738767531) Tao K, Tzou PL, Kosakovsky Pond SL, Ioannidis JPA, Shafer RW (2022) Susceptibility of SARS-CoV-2 omicron variants to therapeutic monoclonal antibodies: systematic review and meta-analysis. Microbiol Spectr. 10(4):e0092622. https://doi.org/10.1128/spectrum.00926-22 . (Epub 2022 Jun 14). (PMID: 10.1128/spectrum.00926-2235700134) Boschi C, Colson P, Bancod A, Moal V, La Scola B (2022) Omicron variant escapes therapeutic monoclonal antibodies (mabs) including recently released Evusheld ® , contrary to 8 prior main variant of concern (VOC). Clin Infect Dis 75(1):e534–e535. https://doi.org/10.1093/cid/ciac143. (PMID: 10.1093/cid/ciac143351719879402686) |
| فهرسة مساهمة: | Keywords: Kidney transplant; Monoclonal antibodies; Prophylaxis; SARS-CoV-2 |
| تواريخ الأحداث: | Date Created: 20240523 Latest Revision: 20240523 |
| رمز التحديث: | 20240523 |
| DOI: | 10.1007/s40620-024-01889-9 |
| PMID: | 38780697 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1724-6059 |
|---|---|
| DOI: | 10.1007/s40620-024-01889-9 |